The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration.
OBJECTIVE
Photodynamic therapy (PDT) has been widely used in the treatment of age-related macular degeneration (AMD). The complement cascade has an important role in the tissue reactions occurring after PDT. The Y402H polymorphism of the complement factor H (CFH) gene has been identified as a risk factor for AMD. Since CFH is central in the regulation of the complement system the authors wanted to analyze whether the CFH Y402H polymorphism modifies the PDT outcome in AMD.


METHODS
A total of 88 patients having been treated with PDT and without further scheduled PDT sessions were analyzed. Depending on the situation at their final PDT session the patients were classified retrospectively as PDT-responders or PDT-nonresponders. All patients were genotyped for the CFH Y402H polymorphism.


RESULTS
The proportion of PDT-responders was 18/26 (69.2%) in patients homozygous for the CFH Y402H risk allele, 34/50 (68.0%) in heterozygous, and 7/12 (58.3%) in patients with the normal genotype (p=0.520). The median number of PDT treatments of the PDT-responders was three for all the genotypes.


CONCLUSIONS
The dysfunction of the CFH related to the risk of AMD and caused by the Y402H polymorphism does not modify the outcome of PDT. Genotyping for CFH Y402H cannot be used to select patients for this treatment.
Seitsonen
S P
SP
Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland. sanna.seitsonen@hus.fi
Jarvela
I E
IE
Meri
S
S
Tommila
P V
PV
Ranta
P H
PH
Immonen
I J
IJ
D000368:Aged; D017242:Complement Factor H / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D010778:Photochemotherapy; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome; D014792:Visual Acuity
C493495:CFH protein, human; D017242:Complement Factor H